Compare PATK & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PATK | BEAM |
|---|---|---|
| Founded | 1959 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.0B |
| IPO Year | 1994 | 2019 |
| Metric | PATK | BEAM |
|---|---|---|
| Price | $90.66 | $28.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $122.75 | $50.75 |
| AVG Volume (30 Days) | 430.3K | ★ 1.8M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ 1.10 | N/A |
| Revenue | ★ $29,000,000.00 | $24,000.00 |
| Revenue This Year | $5.78 | N/A |
| Revenue Next Year | $6.51 | $33.77 |
| P/E Ratio | $82.02 | ★ N/A |
| Revenue Growth | ★ 262.50 | 33.33 |
| 52 Week Low | $83.96 | $15.60 |
| 52 Week High | $148.50 | $36.44 |
| Indicator | PATK | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 40.60 | 47.74 |
| Support Level | $87.53 | $28.50 |
| Resistance Level | $98.39 | $32.01 |
| Average True Range (ATR) | 2.73 | 1.80 |
| MACD | 0.54 | 0.10 |
| Stochastic Oscillator | 27.39 | 41.76 |
Patrick Industries Inc is a component solutions provider for the recreational vehicle (RV), marine, powersports, manufactured housing (MH), and various industrial markets, including single and multi-family housing, hospitality, institutional, and commercial markets. The company operates within two reportable segments, Manufacturing and Distribution. The majority of its revenue is generated from the Manufacturing segment, which offers laminated products utilized to produce furniture, shelving, walls, and countertops; fabricated aluminum products; cabinet products, doors, components, and custom cabinetry; interior passage doors and baggage doors; RV and marine furniture, etc. Geographically, the company mainly operates in the United States, with a small presence in Mexico, China, and Canada.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.